Jan Booij - Nanotechnology

Author Information

Jan Booij is affiliated with the Department of Radiology and Nuclear Medicine at the University of Amsterdam, Amsterdam UMC, Location Academic Medical Center, Amsterdam, The Netherlands. His research primarily focuses on imaging techniques in medical diagnosis and treatment, with a significant emphasis on neurological and psychiatric conditions.

Research Contributions

Jan Booij has made substantial contributions to the field of radiology and nuclear medicine, particularly in the application of advanced imaging techniques such as PET/CT and MRI. His research in 2022 includes studies on quantitative classification and radiomics of [18F]FDG-PET/CT in thyroid nodules, dopaminergic alterations in populations at risk for psychosis, and neuromelanin MRI as a biomarker for treatment resistance in schizophrenia. Additionally, his work extends to the study of neurodegenerative disorders, as evidenced by his research on REM sleep behavior disorder and its association with α-synuclein positivity. Booij's research also explores imaging parameters in breast cancer staging and the detection of sentinel lymph nodes.

Aliases

Jan Booij is also known by the following names: J Booij, J. Booij.

Publication and Citation Metrics

Metric	Value
Citation Count	17,840
H-index	72
Paper Count	479

Publications:

Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodules

DOI: 10.1007/s00259-022-05712-0

Year: 2022

Dopaminergic alterations in populations at increased risk for psychosis: A systematic review of imaging findings

DOI: 10.1016/j.pneurobio.2022.102265

Year: 2022

Neuromelanin MRI as biomarker for treatment resistance in first episode schizophrenia patients

DOI: 10.1016/j.nsa.2022.100077

Year: 2022

Neuromelanin MRI as Biomarker for Treatment Resistance in First Episode Schizophrenia

DOI: 10.1016/j.biopsych.2022.02.171

Year: 2022

Paraneoplastic Cerebellar Syndrome Presented as Cerebellar Hypermetabolism in a Patient With Occult Breast Carcinoma

DOI:

Year: 2022

Abstract P3-02-11: Towards a new standard for staging: A comparative study of [18F]FES PET/CT vs [18F]FDG PET/CT in patients with clinical stage II/III and locoregional recurrent estrogen receptor positive breast cancer

DOI: 10.1158/1538-7445.sabcs21-p3-02-11

Year: 2022

Anatomical Breast Imaging Derived Parameters Do Not Provide Incremental Information In Prediction of Nonvisualization of Sentinel Lymph Nodes On Lymphoscintigraphy

DOI: 10.21203/rs.3.rs-1187890/v1

Year: 2022

Cerebral [18F]-FDOPA Uptake in Autism Spectrum Disorder and Its Association with Autistic Traits

DOI: 10.3390/diagnostics11122404

Year: 2021

Consistent skin α-synuclein positivity in REM sleep behavior disorder - A two center two-to-four-year follow-up study.

DOI: 10.1016/j.parkreldis.2021.04.007

Year: 2021

No evidence for decreased D2/3 receptor availability and frontal hypoperfusion in subjects with compulsive pornography use

DOI: 10.1016/j.pscychresns.2021.111284

Year: 2021

What is a Nanotechnology Spill?

What Are the Regulatory Frameworks?

How Does Nanotechnology Enhance Mild Soap?

How Do Postdoctoral Researchers Contribute to the Field?

What is EUV Lithography?

How Do These Platforms Support Research in Nanotechnology?

How Does a Quadrupole Mass Analyzer Work?

Why is Surface Fouling a Concern in Nanotechnology?

How Do They Differ from Traditional Resists?

What are the Key Features of FullProf?

Partnered Content Networks

Relevant Topics